Compare HIX & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIX | EBS |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 351.3M | 303.3M |
| IPO Year | 1998 | 2006 |
| Metric | HIX | EBS |
|---|---|---|
| Price | $3.32 | $5.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 395.8K | ★ 917.9K |
| Earning Date | 01-01-0001 | 11-02-2026 |
| Dividend Yield | ★ 13.14% | N/A |
| EPS Growth | N/A | ★ 125.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $742,900,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.03 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $4.36 |
| 52 Week High | $4.33 | $14.06 |
| Indicator | HIX | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 35.12 | 28.53 |
| Support Level | N/A | $4.36 |
| Resistance Level | $4.04 | $7.18 |
| Average True Range (ATR) | 0.05 | 0.44 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 6.52 | 5.06 |
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its primary investment objective is to maximize current income by investing at least 80% of its net assets, plus any borrowings for investment purposes, in high-yield debt securities. As a secondary objective, the Fund seeks capital appreciation to the extent consistent with its objective of seeking to maximize current income.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.